
Humans with lower motor excitability have reduced working memory than humans with higher motor excitability, researchers have found.
In the study, that included 188 healthy young subjects, the scientists were able to show that subjects with a high motor excitability had increased working memory performance as compared to subjects with a low excitability.
Advertisement
By measuring the excitability of the motor cortex, conclusions can be drawn as to the excitability of other cortical areas, Nathalie Schicktanz, doctoral student and first author of the study, said.
The results might also have important clinical implications, as working memory deficits are a component of many neuropsychiatric disorders, such as schizophrenia or attention deficit hyperactivity disorder. In a next step, the scientists plan to study the relation between neuronal excitability and memory on a molecular level.
The study is part of a project lead by Prof. Dominique de Quervain and Prof. Andreas Papassotiropoulos. The project uses transcranial magnetic stimulation to study the cognitive functions in humans. The goal is to identify the neurobiological and molecular mechanisms of human memory.
Source: ANI
Advertisement
The study is part of a project lead by Prof. Dominique de Quervain and Prof. Andreas Papassotiropoulos. The project uses transcranial magnetic stimulation to study the cognitive functions in humans. The goal is to identify the neurobiological and molecular mechanisms of human memory.
Source: ANI
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Research News

South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.

Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.

By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.

Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.

Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.